Bardy Diagnostics

Seattle, Washington-based Bardy Diagnostics develops non-invasive cardiac monitoring solutions, primarily focusing on comfortable, week-long wear ambulatory patches designed to detect arrhythmias and heart rhythm disorders. The company generates revenue by selling its proprietary Carnation Ambulatory Monitor devices, which utilize P-wave centric detection, and providing remote electrocardiogram analysis through its Independent Diagnostic Testing Facility. Prior to its strategic exit, the enterprise raised over $71 million in venture funding, which included a $35.5 million Series B round in 2019. Medical technology firm Hillrom acquired the business for $375 million in 2021, and it subsequently became part of Baxter International following a broader corporate merger. Cardiac electrophysiologist Gust Bardy founded the startup in 2013, later appointing Kevin Hykes as chief executive officer while attracting backing from Matrix Capital Management, HealthQuest Capital, Lumira Ventures, and River Cities Capital Fund.